Medicure Inc (TSE:MPH)
:MPH
Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$12.52M
Enterprise ValueC$9.58M
Total Cash (Recent Filing)C$3.83M
Total Debt (Recent Filing)C$891.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt gives Medicure structural financial flexibility to fund commercialization, partnerships or R&D without immediate refinancing. Over the next several months this leverage profile reduces bankruptcy risk, supports negotiation of deals, and allows time to stabilize operations if losses persist.
Top-line Growth MomentumSustained revenue growth signals enduring demand for marketed cardiovascular products and improving commercial traction. Continued top-line expansion can drive better fixed-cost absorption and create room to reinvest in sales or development, improving the company's ability to regain positive operating leverage.
Focused Specialty FranchiseA clear focus on cardiovascular therapies creates concentrated expertise, targeted distribution channels and closer payer/provider relationships. This niche positioning supports durable market niches, potential for licensing/partnerships and a clearer commercialization roadmap versus a broad, unfocused portfolio.
Bears Say
Deteriorating ProfitabilityA sharp increase in net losses erodes retained capital and highlights weak operating leverage. If losses remain, the company will face pressure to cut costs or raise capital, which can dilute shareholders or constrain strategic investments, undermining its ability to sustainably commercialize products.
Negative Cash GenerationThe shift to negative operating and free cash flow increases reliance on external funding to run operations and support development. Structurally weak cash generation raises execution risk for commercialization and R&D, and shortens the runway to remedial actions absent improved margins or financing.
Shrinking Equity CushionA material drop in shareholders' equity reduces the capital buffer against future losses or product setbacks. Even with low debt, a smaller equity base limits strategic flexibility, increases the potential dilutive impact of any new financing, and raises solvency risk if negative earnings persist.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$12.52M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Jun 02, 2026 which is in 12 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―